Efficacy of Belimumab for Treatment of Cutaneous Manifestations of Systemic Lupus Erythematosus; A Report of Three Cases

DOI Web Site

Bibliographic Information

Other Title
  • 当院でベリムマブを投与した全身性エリテマトーデス3例の使用経験
  • トウ イン デ ベリムマブ オ トウヨ シタ ゼンシンセイ エリテマトーデス 3レイ ノ シヨウ ケイケン

Search this article

Description

<p>Cutaneous manifestations of systemic lupus erythematosus (SLE) are occasionally resistant to conventional treatment options.</p><p>Belimumab is the first biological agent for the treatment of SLE, it was approved in 2017. We report three cases of SLE with refractory cutaneous manifestations successfully treated with belimumab.</p><p>Case 1: A 27-year-old man developed multiple lupus erythematosus profundus lesions on his scalp, face, and trunk.</p><p>Case 2: A 33-year-old woman had chilblain lupus erythematosus on her nose.</p><p>Case 3: A 17-year-old female adolescent developed refractory butterfly-shaped erythema and multiple incomplete hair loss patches scattered on her scalp associated with erythema. All the patients received oral corticosteroids and immunosuppressants for SLE; however, none of them had an sufficient response. Belimumab was effective not only against systemic symptoms but also successful in treating the severe cutaneous manifestations of SLE; therefore, we could reduce the oral corticosteroid dosage. Based on these findings, we propose belimumab as an effective treatment option for refractory cutaneous manifestations of SLE.</p>

Journal

Keywords

Details 詳細情報について

Report a problem

Back to top